Last updated: February 20, 2026
What is Darvon Compound-65?
Darvon Compound-65 is a proprietary combination analgesic formulation containing propoxyphene, aspirin, and caffeine. Historically marketed as a pain reliever, its formulation aims to combine the central action of propoxyphene with the anti-inflammatory effects of aspirin and stimulatory properties of caffeine.
Note: Propoxyphene was withdrawn from many markets due to safety concerns related to overdose risk and cardiac toxicity.
Regulatory Status and Market Approval
Current Market Approval
- United States: Propoxyphene products like Darvon and Darvon Compound-65 were withdrawn from the U.S. market by the FDA in 2010.
- Global: Several countries have similarly banned or restricted these formulations.
- Remaining Markets: Limited; some jurisdictions still permit specific formulations under strict regulation.
Regulatory Challenges
- Safety Concerns: Propoxyphene's association with cardiac arrhythmias and fatalities led to withdrawal.
- Legal Actions: Numerous lawsuits related to overdose risks.
- Reformulation Trends: Companies have shifted focus toward newer pain management drugs with improved safety profiles.
Patent Landscape and Intellectual Property
- The original patents for Darvon and its combinations expired decades ago.
- No recent patents filed for Darvon Compound-65 formulations.
- Limited patent protection for reformulated or new analogs of propoxyphene due to safety issues.
Commercial Viability and Market Dynamics
Market Decline
- The global demand for propoxyphene-based medications has plummeted.
- Many formulations have been voluntarily withdrawn or banned.
- Tylenol, ibuprofen, and newer opioids dominate the pain management landscape.
Potential for Reformulation
- No current pipeline or reformulation plans publicly disclosed.
- Investment in new formulations containing propoxyphene unlikely due to safety profile.
- Development of safer alternatives is the industry trend.
Competitive and Regulatory Environment
| Aspect |
Details |
| Major Competitors |
Oxycodone, hydrocodone, NSAIDs, acetaminophen-based analgesics |
| Regulatory Hurdles |
Safety profile issues, market bans, strict labeling requirements |
| R&D Trends |
Focus shifted to non-opioid analgesics, multimodal pain therapies |
Investment Risks and Opportunities
Risks
- Regulatory Rejection: High risk of non-approval or market withdrawal due to safety history.
- Market Obsolescence: Existing formulations largely obsolete; market share negligible.
- Liability Exposure: Potential for legal liability related to past safety issues.
- Patent Loss: No proprietary advantage; generic dominance possible.
Opportunities
- Repurposing Potential: Limited, as safety concerns overshadow potential benefits.
- Novel Delivery Systems: Unlikely to succeed without safety improvements.
- Market Niche: Almost nonexistent; limited to historical or legacy product purchase.
Financial Outlook
- Probable revenue decline to negligible levels.
- R&D investments unlikely to yield commercial returns.
- Potential liabilities and legal costs rising.
Key Takeaways
- Darvon Compound-65's formulation faces near-total market withdrawal in major jurisdictions.
- Regulatory environment imposes significant barriers due to safety concerns.
- Patent protections have expired; limited scope for innovation or differentiation.
- Industry focus has shifted toward safer, more effective analgesics.
- Investment risks are high; opportunities are minimal without significant reformulation.
FAQs
Q1: Can Darvon Compound-65 return to the market?
A: Unlikely due to safety concerns and regulatory bans.
Q2: Are there any ongoing R&D efforts for propoxyphene-based drugs?
A: No publicly available projects; focus has shifted to alternative therapies.
Q3: What are the main safety issues with Darvon Compound-65?
A: Cardiac arrhythmias, overdose risk, and potential fatalities.
Q4: Is there a legal liability associated with Darvon products?
A: Yes, past and ongoing lawsuits exist related to safety and overdose.
Q5: Is there investment value in companies holding Darvon Compound-65 assets?
A: No, due to obsolescence, regulatory restrictions, and safety concerns.
References
- Food and Drug Administration. (2010). FDA Statement on Propoxyphene.
- European Medicines Agency. (2012). Safety review of propoxyphene-containing medicines.
- U.S. Patent and Trademark Office. (2022). Patent status for analgesic formulations.
- Market Research Future. (2023). Global pain management drugs market analysis.
- Reports on legal action against Darvon products (court documents, 2010-2022).
